Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

Barnett, Anthony H, Mithal, Ambrish, Manassie, Jenny, Jones, Russell, Rattunde, Henning, Woerle, Hans J and Broedl, Uli C (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology, 2 (5). pp. 369-384. ISSN 22138587. This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs

Full text not available from this repository.

Abstract

Diabetes is a leading cause of chronic kidney disease (CKD) worldwide. Optimum glycaemic control in patients with type 2 diabetes is important to minimise the risk of microvascular and macrovascular complications and to slow the progression of CKD. We assessed the efficacy and safety of empagliflozin as an add-on treatment in patients with type 2 diabetes and CKD.

Item Type:	Article
Additional Information:	This article is accessible to all HEFT staff and students via NHS Evidence www.evidence.nhs.uk by using their HEFT Athens login IDs
Subjects:	WJ Urogenital system. Urology WK Endocrine system. Endocrinology
Divisions:	Ambulatory Care > Diabetes
Related URLs:	http://www.thelancet.com/journals/landia...
Depositing User:	Users 7 not found.
Date Deposited:	26 Jun 2014 08:40
Last Modified:	26 Jun 2014 08:40
URI:	http://www.repository.uhblibrary.co.uk/id/eprint/342

Actions (login required)

View Item